Voluntary recall of specific batches of ALK Peanut SPT in Australia
AMLS is voluntarily withdrawing specific batches of ALK peanut allergenic extract for diagnostic skin prick testing (SPT) in Australia. AMSL will collect affected batches and will provide replacement products. All existing stock has been removed from the AMSL inventory and will be returned to ALK.
ALK-Abelló, Inc. has been made aware of multiple adverse events from Allergists in Australia resulting from diagnostic SPT using specific batches of ALK Peanut SPT product in 5mL and 10mL packaging configurations at 1:10 w/v. Information on the specific batches is included in this document 
Market Withdrawl Letter for Peanut Diagnostic177.98 KB.
According to these reports, individuals who were test-negative using the above product lots subsequently experienced allergic reactions to peanut.
If there are any questions, contact the AMSL Allergy team:
Ph +61 (02) 9882 3666 | +61 (0)448 022 855
2 McCabe Place, Chatswood NSW 2067
PO Box 5197 Chatswood West NSW 1515
This news item was issued on 16 December 2022 by Jill Smith, CEO of the Australasian Society of Clinical Immunology and Allergy (ASCIA). ASCIA is the peak professional body for clinical immunology and allergy in Australia and New Zealand.
